血管生成素样蛋白3是2型糖尿病患者视网膜病变的潜在生物标志物
横断面研究纳入1192例2型糖尿病患者,检测血清血管生成素样蛋白3(ANGPTL3)、血管生成素样蛋白4(ANGPTL4)及VEGF等标志物并行眼底分级。多因素校正后ANGPTL3与各阶段糖尿病视网膜病变风险独立相关,ANGPTL4无显著关联。作者认为阻断视网膜ANGPTL3信号可能延缓糖尿病视网膜病变的发生发展。
要点
- 1192例2型糖尿病患者中,非增殖期糖尿病视网膜病变426例(35.7%),增殖期56例(4.5%)。
- 校正混杂因素后,ANGPTL3与糖尿病视网膜病变各阶段风险独立相关。
- ANGPTL4与糖尿病视网膜病变各阶段风险均无显著关联。
核心结论
- ANGPTL3在所有阶段均与2型糖尿病患者糖尿病视网膜病变进展独立且强相关。
- 作者认为阻断视网膜ANGPTL3信号可能延缓2型糖尿病患者糖尿病视网膜病变的发生和发展。
研究设计与样本
- 横断面研究,纳入1192例2型糖尿病患者。
- 采用酶联免疫吸附试验(ELISA)定量血清ANGPTL3、ANGPTL4、高敏C反应蛋白(CRP)、血管黏附分子-1(VCAM-1)、细胞内黏附分子-1(ICAM-1)和血管内皮生长因子(VEGF)。
- 采集视网膜图像评估糖尿病视网膜病变分级,并采用多因素校正logistic分析估计各生物标志物与糖尿病视网膜病变分期的关联。
主要发现
- 1192例2型糖尿病患者中,非增殖期糖尿病视网膜病变426例(35.7%),增殖期糖尿病视网膜病变56例(4.5%)。
- 有糖尿病视网膜病变 vs 无糖尿病视网膜病变(n=710 vs 482)的比值比:ANGPTL3为1.23(95%CI 1.08-1.40,P=.002),ANGPTL4为0.90(95%CI 0.79-1.02,P=.095),VEGF为1.14(95%CI 1.00-1.29,P=.044)。
- 无糖尿病视网膜病变 vs 非增殖期糖尿病视网膜病变(n=710 vs 426)的比值比:ANGPTL3为1.16(95%CI 1.01-1.32,P=.036),ANGPTL4为0.90(95%CI 0.79-1.04,P=.15),VEGF为1.14(95%CI 1.00-1.31,P=.045)。
- 非增殖期糖尿病视网膜病变 vs 增殖期糖尿病视网膜病变(n=426 vs 56)的比值比:血清ANGPTL3为1.47(95%CI 1.03-2.10,P=.035),ANGPTL4为0.96(95%CI 0.69-1.35,P=.83),VEGF为1.05(95%CI 0.77-1.45,P=.74)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) are differentially associated with the severity of retinopathy in patients with type 2 diabetes mellitus (T2DM). DESIGN: Cross-sectional study. METHODS: Serum levels of ANGPTL3, ANGPTL4, high-sensitivity C-reactive protein (CRP), vascular adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1), and vascular endothelial growth factor (VEGF) were quantified by ELISA. Retinal images were recorded to assess the grade of diabetic retinopathy (DR). Multivariable-adjusted logistic analysis was performed to estimate the association of each biomarker and DR stage. RESULTS: Among 1192 T2DM patients, 426 (35.7%) had nonproliferative diabetic retinopathy (NPDR) and 56 (4.5%) had proliferative diabetic retinopathy (PDR). After adjusting for covariables, the odds ratios expressing the risk of having DR vs no DR (n = 710 vs 482) were 1.23 (95% confidence interval [CI], 1.08-1.40, P = .002) for ANGPTL3; 0.90 (95% CI, 0.79-1.02; P = .095) for ANGPTL4; and 1.14 (95% CI, 1.00-1.29; P = .044) for VEGF. The risk of having no DR vs NPDR (n = 710 vs 426) was 1.16 (95% CI, 1.01-1.32; P = .036) for ANGPTL3; 0.90 (95% CI, 0.79-1.04; P = .15) for ANGPTL4; and 1.14 (95% CI, 1.00-1.31; P = .045) for VEGF. The odds ratios of having NPDR vs PDR (n = 426 vs 56) was 1.47 (95% CI, 1.03-2.10; P = .035) for serum ANGPTL3; 0.96 (95% CI, 0.69-1.35; P = .83) for ANGPTL4; and 1.05 (95% CI, 0.77-1.45; P = .74) for VEGF. CONCLUSIONS: ANGPTL3 is independently and strongly associated with DR progression in all stages. Blockade of ANGPTL3 signal in retina might postpone the onset and development of DR in T2DM patients.
引用
- Yu CG, Yuan SS, Yang LY, et al. Angiopoietin-like 3 Is a Potential Biomarker for Retinopathy in Type 2 Diabetic Patients. Am J Ophthalmol. 2018. PMID: 29621508. doi:10.1016/j.ajo.2018.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。